89 related articles for article (PubMed ID: 2117625)
1. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients.
Roberts RB; Jurica K; Meyer WA; Paxton H; Makuch RW
J Infect Dis; 1990 Sep; 162(3):638-42. PubMed ID: 2117625
[TBL] [Abstract][Full Text] [Related]
2. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group.
Roberts RB; Hollinger FB; Parks WP; Rasheed S; Laurence J; Heseltine PN; Makuch RW; Lubina JA; Johnson KM
AIDS; 1990 Jan; 4(1):67-72. PubMed ID: 1690551
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation.
Crumpacker C; Heagy W; Bubley G; Monroe JE; Finberg R; Hussey S; Schnipper L; Lucey D; Lee TH; McLane MF
Ann Intern Med; 1987 Nov; 107(5):664-74. PubMed ID: 3662279
[TBL] [Abstract][Full Text] [Related]
4. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
[TBL] [Abstract][Full Text] [Related]
5. Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients. The Ribavirin ARC Study Group.
J Acquir Immune Defic Syndr (1988); 1993 Jan; 6(1):32-41. PubMed ID: 8417172
[TBL] [Abstract][Full Text] [Related]
6. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.
Spector SA; Kennedy C; McCutchan JA; Bozzette SA; Straube RG; Connor JD; Richman DD
J Infect Dis; 1989 May; 159(5):822-8. PubMed ID: 2496173
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
[TBL] [Abstract][Full Text] [Related]
8. Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men.
Schulof RS; Parenti DM; Simon GL; Paxton H; Meyer WA; Schlesselman SB; Courtless J; LeLacheur S; Sztein MB
J Acquir Immune Defic Syndr (1988); 1990; 3(5):485-92. PubMed ID: 1691287
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Merigan TC; Skowron G
Am J Med; 1990 May; 88(5B):11S-15S. PubMed ID: 2159703
[TBL] [Abstract][Full Text] [Related]
11. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts RB; Dickinson GM; Heseltine PN; Leedom JM; Mansell PW; Rodriguez S; Johnson KM; Lubina JA; Makuch RW
J Acquir Immune Defic Syndr (1988); 1990; 3(9):884-92. PubMed ID: 1974628
[TBL] [Abstract][Full Text] [Related]
12. Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection.
Ohlsson-Wilhelm BM; Cory JM; Kessler HA; Eyster ME; Rapp F; Landay A
J Infect Dis; 1990 Nov; 162(5):1018-24. PubMed ID: 1977803
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome.
Roberts RB; Laskin OL; Laurence J; Scavuzzo D; Murray HW; Kim YT; Connor JD
Clin Pharmacol Ther; 1987 Oct; 42(4):365-73. PubMed ID: 2444379
[TBL] [Abstract][Full Text] [Related]
14. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 (HIV-1) genomic sequences and distinct changes in CD8+ lymphocytes precede detectable levels of HIV-1 antibodies in high-risk homosexuals.
Yagi MJ; Joesten ME; Wallace J; Roboz JP; Bekesi JG
J Infect Dis; 1991 Jul; 164(1):183-8. PubMed ID: 1829106
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
[TBL] [Abstract][Full Text] [Related]
17. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
[TBL] [Abstract][Full Text] [Related]
18. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
Saag MS; Crain MJ; Decker WD; Campbell-Hill S; Robinson S; Brown WE; Leuther M; Whitley RJ; Hahn BH; Shaw GM
J Infect Dis; 1991 Jul; 164(1):72-80. PubMed ID: 1676046
[TBL] [Abstract][Full Text] [Related]
19. Lack of HPA-23 antiviral activity in HIV-infected patients without AIDS.
Burgard M; Sansonetti P; Vittecoq D; Descamps P; Guetard D; Herson S; Rozenbaum W; Rouzioux C
AIDS; 1989 Oct; 3(10):665-8. PubMed ID: 2480798
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
